2062 - In Vivo Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), Against Seasonal Subtypes of Influenza in Prophylaxis in Immune Competent Mice, and in a Severe Immunodeficient (SCID) Mouse Model

Presenting Author(s)

• 

  James Levin, PhD

  Senior Director of Preclinical Development
  Cidara Therapeutics
  San Diego, CA, United States

Co-Author(s)

• 

  Simon Döhrmann, PhD

  Senior Scientist
  Cidara Therapeutics
  San Diego, California, United States
• JC

  Jason N. Cole, Ph.D.

  Associate Director
  Cidara Therapeutics
  San Diego, California, United States
• KA

  Karin Amundson, BSc

  Senior Research Associate
  Cidara Therapeutics
  San Diego, California, United States
• AB

  Allen Borchardt, PhD

  Director
  Cidara Therapeutics
  San Diego, California, United States
• TB

  Thomas P. Brady, Ph.D.

  Senior Principal Scientist II
  Cidara Therapeutics
  San Diego, California, United States
• TL

  Thanh Lam, PhD

  Senior Scientist
  Cidara Therapeutics
  San Diego, California, United States
• JF

  Joanne Fortier, BSc

  Research Associate
  Cidara Therapeutics
  San Diego, CA, United States
• AA

  Amanda Almaguer, Bachelors

  Scientist
  Cidara Therapeutics
  San Diego, California, United States
• LT

  Leslie W. Tari, Ph.D.

  Chief Scientific Officer
  Cidara Therapeutics
  San Diego, California, United States